Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Low-dose Naltrexone Therapy for Psoriasis

Author(s):  Weinstock Leonard B, Cottel Jill, Aldridge Lindsey, Egeberg Alexander

Issue:  Mar/Apr 2020 - Volume 24, Number 2
View All Articles in Issue

Page(s):  94-96

Download in electronic PDF format for $65

Abstract:  Safe, inexpensive, and convenient psoriasis therapy is desirable. Two recent case reports suggested that low-dose naltrexone is effective. Cases from our practice are presented in order to further the evidence of efficacy and safety of low-dose naltrexone in the treatment of psoriasis. Patients included 13 females, 2 males; mean age 57 years; mean psoriasis duration 16 years. Of the patients, 8 had psoriatic arthritis. In the past, 5 had completely failed and 10 had partially responded to =1 topical therapies. Patients used a self-assessed Likert scale on the effect of low-dose naltrexone on their psoriasis: 1 - worse; 2 – unchanged; 3 - slightly improved; 4 - somewhat improved; 5 – marked improvement. The response to 4.5 mg of oral naltrexone was as follows: 8/15 marked improvement; 2/15 somewhat improved; and 5/15 unchanged. Three adverse events included insomnia, diarrhea, and self-limited headache. Marked improvement was seen by 53% of the 15 patients. Low-dose naltrexone regulates lymphocyte responses, reduces cytokine production, and likely reduces mast cell activity. Low-dose naltrexone is safe, inexpensive, and appears be effective in this open-label study.

Related Keywords: Leonard B. Weinstock, MD, Jill Cottel, MD, Lindsey Aldridge, RN, Alexander Egeberg, MD, PhD, low-dose naltrexone, plaque psoriasis, psoriatic arthritis, skin disorders, dermatosis, pruritus, adverse effects, clinical study

Related Categories: DERMATOLOGY, ADVERSE DRUG EVENTS, ALLERGY/IMMUNOLOGY/INFLAMMATION, PATIENT ASSESSMENT

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Low-dose Naltrexone Therapy for Psoriasis
Weinstock Leonard B
, Cottel Jill, Aldridge Lindsey, Egeberg Alexander
Mar/Apr 2020
Pg. 94-96

Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders
Ploesser Jennifer
, Weinstock Leonard B, Thomas Erin
Mar/Apr 2010
Pg. 171-173

Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report
Muller George
, Grieshaber Robert, Talley J Floyd, Riepl Mike, Fellows Don
Jul/Aug 2018
Pg. 270-278

Basics of Compounding: Clinical Studies
Allen Loyd V Jr
Nov/Dec 2002
Pg. 443-447

Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients
Sturn Kayla M
, Collin Michael
May/Jun 2016
Pg. 197-201

Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Brown Scott
, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
May/Jun 2010
Pg. 182-192

Skin Disorders in Horses; Case Report: Tripelennamine in the Treatment of Skin Disorders in Horses
Williams LaVonn A
, Fokken Dawn
Sep/Oct 2009
Pg. 386-389

Stability of Tranexamic Acid in 0.9% Sodium Chloride, Stored in Type 1 Glass Vials and Ethylene/Propylene Copolymer Plastic Containers
McCluskey Susan V
, Sztajnkrycer Matthew D, Jenkins Donald A, Zietlow Scott P, Berns Kathleen S, Park Myung S
Sep/Oct 2014
Pg. 432-437

The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia
Cote Brianna
, Ross Bethany, Fortner Jeff, Rao Deepa
May/Jun 2018
Pg. 252-256

Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine
Catry Emilie
, Colsoul Marie-Louise, Closset Melanie, Hubert Justine, Soumoy Laura, Bihin Benoit, Thiry Emmanuell, Jamart Jacques, Hecq Jean-Daniel, Galanti Laurence
May/Jun 2022
Pg. 248-254

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions